The combination of anti-CXCL1-CXCR2 blockade with doxorubicin in HCC treatment was found to reduce TAM recruitment in the tumor microenvironment (TME) and inhibit tumor progression (32). This evidence concerns the gene CXCR2 and neoplasm.